Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 4/2012

01-07-2012 | SSIEM Symposium 2011

Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, follow-up and quality assurance

Authors: Peter Burgard, Kathrin Rupp, Martin Lindner, Gisela Haege, Tessel Rigter, Stephanie S. Weinreich, J. Gerard Loeber, Domenica Taruscio, Luciano Vittozzi, Martina C. Cornel, Georg F. Hoffmann

Published in: Journal of Inherited Metabolic Disease | Issue 4/2012

Login to get access

Abstract

In a survey conducted in 2010/2011 data from the 28 EU member states, four EU candidate states (Croatia, FYROM, Iceland, Turkey), three potential EU candidate states (Bosnia Herzegovina, Montenegro, Serbia), and two EFTA states (Norway and Switzerland) were collected. The status and function of newborn screening (NBS) programmes were investigated from the information to prospective parents and the public via confirmation of a positive screening result up to decisions on treatment. This article summarises the results from screening laboratory findings to start of treatment. In addition we asked about the existence of feedback loops reporting the conclusions of confirmation of screening results to the screening laboratory and communication of long-term outcome to diagnostic units and possibly existing central registries. Parallel to the description of actual practices of where, how and by whom the different steps of the programmes are executed, we also asked for the existence of guidelines or directives regulating the screening programmes, material to support information of parents about diagnoses and treatment and training facilities for professionals involved in the programmes. This survey gives a first comprehensive overview of the steps following a positive screening result in European NBS programmes. The 37 data sets reveal substantial variation of national screening panels, but also a lot of similarities. Analysis across all countries revealed that actual practice is often organised but not regulated by guidelines. Material to inform patients is available more often for explaining treatment (69 %) than explaining the necessity of confirmatory diagnostics (41 %). Training of professionals is rarely regulated by a guideline (2 %), but is offered for paediatricians (40 %) and dieticians (29 %) and only rarely for other professions (e.g. geneticists, clinical nurse specialists, psychologists). Registry-based evaluation of long-term outcome is as yet almost nonexistent (3 %).
Appendix
Available only for authorised users
Literature
go back to reference Auchus RJ, Witchel SF, Leight KR, Aisenberg J, Azziz R, Bachega TA, Baker LA, Baratz AB, Baskin LS, Berenbaum SA, Breault DT, Cerame BI, Conway GS, Eugster EA, Fracassa S, Gearhart JP, Geffner ME, Harris KB, Hurwitz RS, Katz AL, Kalro BN, Lee PA, Alger Lin G, Loechner KJ, Marshall I, Merke DP, Migeon CJ, Miller WL, Nenadovich TL, Oberfield SE, Pass KA, Poppas DP, Lloyd-Puryear MA, Quigley CA, Riepe FG, Rink RC, Rivkees SA, Sandberg DE, Schaeffer TL, Schlussel RN, Schneck FX, Seely EW, Snyder D, Speiser PW, Therrell BL, Vanryzin C, Vogiatzi MG, Wajnrajch MP, White PC, Zuckerman AE (2010) Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation Initiative. Int J Pediatr Endocrinol 2010:275213PubMedCrossRef Auchus RJ, Witchel SF, Leight KR, Aisenberg J, Azziz R, Bachega TA, Baker LA, Baratz AB, Baskin LS, Berenbaum SA, Breault DT, Cerame BI, Conway GS, Eugster EA, Fracassa S, Gearhart JP, Geffner ME, Harris KB, Hurwitz RS, Katz AL, Kalro BN, Lee PA, Alger Lin G, Loechner KJ, Marshall I, Merke DP, Migeon CJ, Miller WL, Nenadovich TL, Oberfield SE, Pass KA, Poppas DP, Lloyd-Puryear MA, Quigley CA, Riepe FG, Rink RC, Rivkees SA, Sandberg DE, Schaeffer TL, Schlussel RN, Schneck FX, Seely EW, Snyder D, Speiser PW, Therrell BL, Vanryzin C, Vogiatzi MG, Wajnrajch MP, White PC, Zuckerman AE (2010) Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation Initiative. Int J Pediatr Endocrinol 2010:275213PubMedCrossRef
go back to reference Blumberg MS (1957) Evaluating health screening procedures. Operations Research 5:351–360CrossRef Blumberg MS (1957) Evaluating health screening procedures. Operations Research 5:351–360CrossRef
go back to reference Castellani C, Southern K, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, de Monestrol I, Farrell P, Feilcke M, Férec C, Gartner S, K G, Hammermann J, Kashirskaya N, Loeber G, Macek M, G M, Reiman A, Rizzotti P, Sammon A, Dands D, Smyth A, Sommerburg O, Torresani T, Travert G, Vernooji A & Elborn S (2009) European best practice guidelines for cystic fibrosis neonatal screening. Journal of Cystic Fibrosis 8:153–73 Castellani C, Southern K, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, de Monestrol I, Farrell P, Feilcke M, Férec C, Gartner S, K G, Hammermann J, Kashirskaya N, Loeber G, Macek M, G M, Reiman A, Rizzotti P, Sammon A, Dands D, Smyth A, Sommerburg O, Torresani T, Travert G, Vernooji A & Elborn S (2009) European best practice guidelines for cystic fibrosis neonatal screening. Journal of Cystic Fibrosis 8:153–73
go back to reference Drummond MF, Sculpher M.J, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd edition. Oxford University Press Drummond MF, Sculpher M.J, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd edition. Oxford University Press
go back to reference European Commission (2009) Complete Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Official Journal of the European Communities C151:7–10 European Commission (2009) Complete Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Official Journal of the European Communities C151:7–10
go back to reference Fant KE, Clark SJ, Kemper AR (2005) Completeness and complexity of information available to parents from newborn-screening programmes. Pediatrics 115(5):1268–1272PubMedCrossRef Fant KE, Clark SJ, Kemper AR (2005) Completeness and complexity of information available to parents from newborn-screening programmes. Pediatrics 115(5):1268–1272PubMedCrossRef
go back to reference Heringer J, Boy SP, Ensenauer R, Assmann B, Zschocke J, Harting I, Lücke T, Maier EM, Mühlhausen C, Haege G, Hoffmann GF, Burgard P, Kölker S (2010) Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol 68(5):743–752PubMedCrossRef Heringer J, Boy SP, Ensenauer R, Assmann B, Zschocke J, Harting I, Lücke T, Maier EM, Mühlhausen C, Haege G, Hoffmann GF, Burgard P, Kölker S (2010) Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol 68(5):743–752PubMedCrossRef
go back to reference Hinton C, Feuchtbaum L, Kus C, Kemper A, Berry SA, Levy-Fisch J, Luedtke J, Kays C, Boyle C (2011) What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services´ Advisory Committee on Heritable Disorders in Newborns and Children. Genetics in Medicine 13(10):861–865PubMedCrossRef Hinton C, Feuchtbaum L, Kus C, Kemper A, Berry SA, Levy-Fisch J, Luedtke J, Kays C, Boyle C (2011) What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services´ Advisory Committee on Heritable Disorders in Newborns and Children. Genetics in Medicine 13(10):861–865PubMedCrossRef
go back to reference Kölker S, Christensen E, Leonard JV, Greenberg CR, Boneh A, Burlina AB, Burlina AP, Dixon M, Duran M, Garcia Cazorla A, Goodman SI, Koeller DM, Kyllerman M, Mühlhausen C, Müller E, Okun JG, Wilcken B, Hoffmann GF, Burgard P (2011) Diagnosis and management of glutaric aciduria type I–revised recommendations. J Inherit Metab Dis 34(3):677–694PubMedCrossRef Kölker S, Christensen E, Leonard JV, Greenberg CR, Boneh A, Burlina AB, Burlina AP, Dixon M, Duran M, Garcia Cazorla A, Goodman SI, Koeller DM, Kyllerman M, Mühlhausen C, Müller E, Okun JG, Wilcken B, Hoffmann GF, Burgard P (2011) Diagnosis and management of glutaric aciduria type I–revised recommendations. J Inherit Metab Dis 34(3):677–694PubMedCrossRef
go back to reference Kölker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, Ribes A, Kalkanoglu HS, Lund AM, Merinero B, Wajner M, Troncoso M, Williams M, Walter JH, Campistol J, Marti-Herrero M, Caswill M, Burlina AB, Lagler F, Maier EM, Schwahn B, Tokatli A, Dursun A, Coskun T, Chalmers RA, Koeller DM, Zschocke J, Christensen E, Burgard P, Hoffmann GF (2006) Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 59(6):840–847PubMedCrossRef Kölker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, Ribes A, Kalkanoglu HS, Lund AM, Merinero B, Wajner M, Troncoso M, Williams M, Walter JH, Campistol J, Marti-Herrero M, Caswill M, Burlina AB, Lagler F, Maier EM, Schwahn B, Tokatli A, Dursun A, Coskun T, Chalmers RA, Koeller DM, Zschocke J, Christensen E, Burgard P, Hoffmann GF (2006) Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 59(6):840–847PubMedCrossRef
go back to reference Lindner M. (2010) Konfirmationsdiagnostik bei Verdacht auf angeborene Stoffwechselkrankheiten aus dem Neugeborenenscreening. Leitlinien der Gesellschaft für Kinderheilkunde und Jugendmedizin (DGKJ) und der Arbeitsgemeinschaft für Pädiatrische Stoffwechselstörungen (APS). Leitline Nr. 027/021. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) (http://www.awmf.org/leitlinien/leitlinien-suche.html#result-list, retrieved 2011.12.01) Lindner M. (2010) Konfirmationsdiagnostik bei Verdacht auf angeborene Stoffwechselkrankheiten aus dem Neugeborenenscreening. Leitlinien der Gesellschaft für Kinderheilkunde und Jugendmedizin (DGKJ) und der Arbeitsgemeinschaft für Pädiatrische Stoffwechselstörungen (APS). Leitline Nr. 027/021. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) (http://​www.​awmf.​org/​leitlinien/​leitlinien-suche.​html#result-list, retrieved 2011.12.01)
go back to reference Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, Trefz FK, Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF (2011) Efficacy and outcome of expanded newborn screening for metabolic diseases - report of 10 years from South-West Germany. Orphanet J Rare Dis 6(44) Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, Trefz FK, Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF (2011) Efficacy and outcome of expanded newborn screening for metabolic diseases - report of 10 years from South-West Germany. Orphanet J Rare Dis 6(44)
go back to reference Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp, K, Hoffmann GF, Vittozzi L (2012) Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 - From blood spot to screening result. J Inherit Metab Dis, this issue Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp, K, Hoffmann GF, Vittozzi L (2012) Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 - From blood spot to screening result. J Inherit Metab Dis, this issue
go back to reference Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S (2004) Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 8(12) Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S (2004) Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 8(12)
go back to reference Petros M (2011) Revisiting the Wilson-Jungner criteria: How can supplemental criteria guide public health in the era of genetic screening? Genetics in Medicine 14:129–134 Petros M (2011) Revisiting the Wilson-Jungner criteria: How can supplemental criteria guide public health in the era of genetic screening? Genetics in Medicine 14:129–134
go back to reference Pollitt RJ (2007) Introducing new screens: why are we all doing different things? J Inherit Metab Dis 30(4):423–429PubMedCrossRef Pollitt RJ (2007) Introducing new screens: why are we all doing different things? J Inherit Metab Dis 30(4):423–429PubMedCrossRef
go back to reference Raffle A, Gray M (2007) Screening – Evidence and practice. Oxford University Press, Oxford Raffle A, Gray M (2007) Screening – Evidence and practice. Oxford University Press, Oxford
go back to reference Rembold CM (1998) Number needed to screen: development of a statistic for disease screening. BMJ 317:307–312PubMedCrossRef Rembold CM (1998) Number needed to screen: development of a statistic for disease screening. BMJ 317:307–312PubMedCrossRef
go back to reference van Dyck PC, Edwards ES (2006) A look at newborn screening: today and tomorrow. Pediatrics 117:193 van Dyck PC, Edwards ES (2006) A look at newborn screening: today and tomorrow. Pediatrics 117:193
go back to reference Wilcken B (2011) Newborn screening: how are we travelling, and where should we be going. J Inherit Metab Dis 34(3):569–574PubMedCrossRef Wilcken B (2011) Newborn screening: how are we travelling, and where should we be going. J Inherit Metab Dis 34(3):569–574PubMedCrossRef
go back to reference Wilcken B, Haas M, Joy P, Wiley V, Bowling F, Carpenter K, Christodoulou J, Cowley D, Ellaway C, Fletcher J, Kirk E, Lewis B, McGill J, Peters H, Pitt J, Ranieri E, Yaplito-Lee J, Boneh A (2009) Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 124(2):e241–e248PubMedCrossRef Wilcken B, Haas M, Joy P, Wiley V, Bowling F, Carpenter K, Christodoulou J, Cowley D, Ellaway C, Fletcher J, Kirk E, Lewis B, McGill J, Peters H, Pitt J, Ranieri E, Yaplito-Lee J, Boneh A (2009) Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 124(2):e241–e248PubMedCrossRef
go back to reference Wilcken B, Rinaldo P, Matern D (2012) Newborn screening for inborn errors of metabolism. In: Saudubry JM, van den Berghe G, Walter JH Inborn (eds) Metabolic diseases - diagnosis and treatment, 5th edn. Springer, Heidelberg, pp 76–86 Wilcken B, Rinaldo P, Matern D (2012) Newborn screening for inborn errors of metabolism. In: Saudubry JM, van den Berghe G, Walter JH Inborn (eds) Metabolic diseases - diagnosis and treatment, 5th edn. Springer, Heidelberg, pp 76–86
Metadata
Title
Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, follow-up and quality assurance
Authors
Peter Burgard
Kathrin Rupp
Martin Lindner
Gisela Haege
Tessel Rigter
Stephanie S. Weinreich
J. Gerard Loeber
Domenica Taruscio
Luciano Vittozzi
Martina C. Cornel
Georg F. Hoffmann
Publication date
01-07-2012
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 4/2012
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-012-9484-z

Other articles of this Issue 4/2012

Journal of Inherited Metabolic Disease 4/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.